Drug profile · INN
lutetium (177lu) vipivotide tetraxetan
PLUVICTO
lutetium (177lu) vipivotide tetraxetan (PLUVICTO) is a dna disrupting agent.
Drug details — lutetium (177lu) vipivotide tetraxetan
- Class
- Various (V10)
- Route
- —
- Patents
- 0
- Programs
- 13
- Data quality
- 0.83
Quick answer
lutetium (177lu) vipivotide tetraxetan (PLUVICTO) is a dna disrupting agent.
Key facts
Mechanism of action
DNA disrupting agent
Primary target: DNA
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Recent coverage
Truqap gains US approval in PTEN-deficient metastatic prostate cancer
AstraZeneca’s Truqap (capivasertib) has been approved in the US with abiraterone and prednisone for PTEN-deficient metastatic prostate cancer. The move creates a first-in-class targeted option and a new catalyst to watch for BD teams, investors, and analysts.
New Radiopharmaceutical Shows Promise in Post-Pluvicto Setting, Offering Competitive Insights
A novel radiopharmaceutical is demonstrating promising results in patients who have previously been treated with Pluvicto, signaling a potential shift in the advanced prostate cancer treatment paradigm. This development presents significant competitive implications for companies like Abivax, Fulcrum, Convergent, and Vera.
Novartis Strengthens Prostate Cancer Treatment with Pluvicto
Novartis has reported stronger PSA responses with its drug Pluvicto in earlier-stage prostate cancer, indicating promising developments in oncology. This news could reshape competitive dynamics in the market.
Radioligand Therapies for Prostate Cancer: Market Access and Clinical Insights in APAC
This article delves into the landscape of radioligand therapies for prostate cancer, focusing on market access and clinical insights across the APAC region.
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is lutetium (177lu) vipivotide tetraxetan?
lutetium (177lu) vipivotide tetraxetan (PLUVICTO) is a dna disrupting agent.
What is the brand name for lutetium (177lu) vipivotide tetraxetan?
PLUVICTO is a marketed brand name for lutetium (177lu) vipivotide tetraxetan. Check FDA Drugs@FDA for the current US label holder and prescribing information.